WO2015187840A3 - Methods and formulations for treatment of ocular disorders - Google Patents

Methods and formulations for treatment of ocular disorders Download PDF

Info

Publication number
WO2015187840A3
WO2015187840A3 PCT/US2015/034000 US2015034000W WO2015187840A3 WO 2015187840 A3 WO2015187840 A3 WO 2015187840A3 US 2015034000 W US2015034000 W US 2015034000W WO 2015187840 A3 WO2015187840 A3 WO 2015187840A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
formulations
treatment
ocular disorders
receptor
Prior art date
Application number
PCT/US2015/034000
Other languages
French (fr)
Other versions
WO2015187840A2 (en
Inventor
Scott Cousins
Catherine Bowes RICKMAN
Donald P. Mcdonnell
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of WO2015187840A2 publication Critical patent/WO2015187840A2/en
Publication of WO2015187840A3 publication Critical patent/WO2015187840A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Methods and compositions are provided for treating an ocular disease such as age- related macular degeneration. In some embodiments, a combination of a retinoid X receptor (RXR) modulator and a liver X receptor (LXR) modulator provides an unexpected synergistic effect.
PCT/US2015/034000 2014-06-03 2015-06-03 Methods and formulations for treatment of ocular disorders WO2015187840A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462007112P 2014-06-03 2014-06-03
US62/007,112 2014-06-03

Publications (2)

Publication Number Publication Date
WO2015187840A2 WO2015187840A2 (en) 2015-12-10
WO2015187840A3 true WO2015187840A3 (en) 2016-03-10

Family

ID=54767577

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/034000 WO2015187840A2 (en) 2014-06-03 2015-06-03 Methods and formulations for treatment of ocular disorders

Country Status (1)

Country Link
WO (1) WO2015187840A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020084548A1 (en) 2018-10-26 2020-04-30 Viramal Limited Mucoadhesive gel composition
JP2022514257A (en) * 2018-12-13 2022-02-10 アイノス，インコーポレイテッド LXR agonist in topical eye drops for the treatment of dry eye disease
WO2021009664A1 (en) * 2019-07-15 2021-01-21 Novartis Ag Methods for treating meibomian gland dysfunction with liver x receptor agonists
UY38964A (en) 2019-11-25 2021-06-30 Novartis Ag DERIVATIVES OF 1,2,4-OXADIAZOLE AS AGONISTS OF THE X LIVER RECEPTOR, THEIR USES AND RELATED METHODS CROSS REFERENCE TO RELATED APPLICATIONS
CN111494354B (en) * 2020-04-21 2021-06-22 复旦大学附属眼耳鼻喉科医院 Use of ABCA1 agonist in preparation of medicine for treating eye diseases
EP4340808A1 (en) * 2021-05-20 2024-03-27 Novartis AG Formulations of 3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethyl-1-(2-morpholinoethyl)imidazolidine-2,4-dione

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917082A (en) * 1995-06-06 1999-06-29 Allergan Sales, Inc. 2,4-pentadienoic acid derivatives having retinoid-like biological activity
US20030162758A1 (en) * 2001-12-07 2003-08-28 Schwartz Daniel M. Treatment for age-related macular degeneration (AMD)
US20050095677A1 (en) * 2003-08-18 2005-05-05 Wyeth Novel human LXRalpha variants
US20100047330A1 (en) * 2001-12-07 2010-02-25 Schwartz Daniel M Treatment for dark adaptation
US20110076318A1 (en) * 2004-04-30 2011-03-31 Allergan, Inc. Retinoid-containing sustained release intraocular implants and related matters

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917082A (en) * 1995-06-06 1999-06-29 Allergan Sales, Inc. 2,4-pentadienoic acid derivatives having retinoid-like biological activity
US20030162758A1 (en) * 2001-12-07 2003-08-28 Schwartz Daniel M. Treatment for age-related macular degeneration (AMD)
US20100047330A1 (en) * 2001-12-07 2010-02-25 Schwartz Daniel M Treatment for dark adaptation
US20050095677A1 (en) * 2003-08-18 2005-05-05 Wyeth Novel human LXRalpha variants
US20110076318A1 (en) * 2004-04-30 2011-03-31 Allergan, Inc. Retinoid-containing sustained release intraocular implants and related matters

Also Published As

Publication number Publication date
WO2015187840A2 (en) 2015-12-10

Similar Documents

Publication Publication Date Title
WO2015187840A3 (en) Methods and formulations for treatment of ocular disorders
EP3359662A4 (en) Compositions and methods for treating huntington's disease and related disorders
WO2016172658A3 (en) Microbiome regulators and related uses thereof
WO2015148863A3 (en) Crispr/cas-related methods and compositions for treating sickle cell disease
EP3465212A4 (en) Regulate gut microbiota to treat neurodegenerative disorders
EP3139966A4 (en) Methods and compositions for treating huntington's disease
EP3157463A4 (en) Methods and devices for treating posterior ocular disorders
EP3224278A4 (en) Methods and formulations for treating vascular eye diseases
BR112017011972A2 (en) azabicycloctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal disorders
EP3261620A4 (en) Methods and compositions for treating dry eye disease and other eye disorders
PH12015501942A1 (en) Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders
EP3096617A4 (en) Compositions and methods for treating ocular diseases
EP3585393A4 (en) Formulations for eye treatments
MX2014010537A (en) Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions.
EP3697920A4 (en) Compositions and methods for treating age-related macular degeneration
EP3352749A4 (en) Compounds and compositions for the treatment of ocular disorders
EP3122872A4 (en) Compositions and methods for treating type 1 and type 2 diabetes and related disorders
EP3651747A4 (en) Compositions and methods for the treatment of eye disorders
EP3176163A4 (en) Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient
EP3240577A4 (en) Methods and compositions for treating brain diseases
IL275985A (en) Compositions and methods for treating retinal disorders
EP3411399A4 (en) Antibody-drug synergism technology for treating diseases
EP3618868A4 (en) Methods and compositions for treating allergic ocular diseases
EP3503883A4 (en) Entacapone-related compounds to treat macular degeneration
EP3310353A4 (en) Compositions and methods for treating and diagnosing ocular disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15803429

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15803429

Country of ref document: EP

Kind code of ref document: A2